Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients

被引:23
|
作者
Onal, Cem [1 ]
Ozyigit, Gokhan [2 ]
Guler, Ozan Cem [1 ]
Hurmuz, Pervin [2 ]
Torun, Nese [3 ]
Tuncel, Murat [4 ]
Dolek, Yemliha [1 ]
Yedekci, Yagiz [2 ]
Oymak, Ezgi [5 ]
Tilki, Burak [2 ]
Akyol, Fadil [2 ]
机构
[1] Baskent Univ, Fac Med, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Radiat Oncol, TR-01120 Adana, Turkey
[2] Hacettepe Univ, Fac Med, Dept Radiat Oncol, Ankara, Turkey
[3] Baskent Univ, Fac Med, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Nucl Med, Adana, Turkey
[4] Hacettepe Univ, Fac Med, Dept Nucl Med, Ankara, Turkey
[5] Iskenderun Gelisim Hosp, Div Radiat Oncol, Antakya, Turkey
关键词
Prostate cancer; Radiotherapy; Prostate-specific membrane antigen; Positron emission tomography; Treatment volume; RADICAL PROSTATECTOMY; RADIATION ONCOLOGY; PATTERNS; FAILURE; ADENOCARCINOMA; IRRADIATION; THERAPY; PET/CT;
D O I
10.1016/j.radonc.2020.08.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the distribution of metastatic lymph nodes (LN) detected on Ga-68-PSMA-positron emission tomography/computed tomography (PET/CT) in treatment-naive prostate cancer (PC) patients and to analyze the LN coverage rates of the pelvic fields defined in the GETUG trial and RTOG guidelines and a pelvic field extending superiorly from the L4/L5 interspace. Materials and methods: Ga-68-PSMA-PET/CT images obtained at diagnosis of 138 PC patients were retro-spectively analyzed. The number and locations of Ga-68-PSMA-positive LNs were co-registered with one single-planning CT. The numbers, locations, and sizes of LNs located outside the three pelvic volumes were investigated for the entire cohort and for patients with LN metastasis in the pelvic area only. Results: A total of 441 PSMA-PET-positive LN metastases were identified. The most frequent metastatic LNs were internal iliac LNs (25.2%). Para-aortic and presacral LNs outside the three pelvic fields were present in 20 (14.5%) and 22 patients (15.9%), respectively. The LN coverage rates according to the GETUG trial, the RTOG guidelines, and the pelvic field extending superiorly from L4/L5 were 44.2%, 52.2%, and 71, respectively, in the entire cohort and 51.7%, 61 and 83.1%, respectively, in patients with only pelvic LN metastasis. The number of metastatic LNs was a predictive factor for LNs located outside the three pelvic fields. Conclusions: Extending the cranial margin of the pelvic field from L5/S1 to L4/L5 increases the accuracy of pelvic field irradiation in approximately 20% of patients, highlighting the importance of proximal common iliac irradiation, particularly in patients with multiple LN metastasis. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:222 / 227
页数:6
相关论文
共 50 条
  • [31] Preoperative prediction of lymph node invasion in prostate cancer: Ga-68 PSMA PET or nomograms?
    Kordan, Y.
    Koseoglu, E.
    Sarikaya, A. F.
    Tarim, K.
    Kilic, M.
    Ozkan, A.
    Kiremit, M. C.
    Musaoglu, A.
    Acar, O.
    Canda, A. E.
    Balbay, M. D.
    Esen, T.
    EUROPEAN UROLOGY, 2021, 79 : S1172 - S1173
  • [32] The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer
    Can Öbek
    Tünkut Doğanca
    Emre Demirci
    Meltem Ocak
    Ali Rıza Kural
    Asıf Yıldırım
    Uğur Yücetaş
    Çetin Demirdağ
    Sarper M. Erdoğan
    Levent Kabasakal
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1806 - 1812
  • [33] Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
    Leitsmann, Conrad
    Schmid, Marianne
    Sahlmann, Carsten-Oliver
    Trojan, Lutz
    Strauss, Arne
    FRONTIERS IN SURGERY, 2021, 8
  • [34] Complimentary role of 68Ga-GRPR PET/CT and 68Ga-PSMA PET/CT in initial diagnosis of prostate cancer
    Tang, Y.
    Zhou, M.
    Li, J.
    Chen, B.
    Rao, W.
    Hu, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S215 - S215
  • [35] Complimentary role of 68Ga-GRPR PET/CT and 68GA-PSMA PET/CT in initial diagnosis of prostate cancer
    Gao, X.
    Tang, Y.
    Chen, M.
    Li, J.
    Yin, H.
    Gan, Y.
    Zu, X.
    Cai, Y.
    Hu, S.
    HISTOPATHOLOGY, 2022, 81 : 134 - 134
  • [36] Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease
    Furman, Ben
    Michaeli, Tal Falick
    Den, Robert
    Ben Haim, Simona
    Popovtzer, Aron
    Wygoda, Marc
    Blumenfeld, Philip
    CANCER IMAGING, 2024, 24 (01)
  • [37] Evaluation of Ga-68-PSMA PET/CT imaging in patients with prostate cancer and value of early pelvic imaging
    Akyel, R.
    Demirci, E.
    Ocak, M.
    Nematyazar, J.
    Aygun, A.
    Halac, M.
    Talat, Z.
    Araman, A.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S235 - S235
  • [38] Predictor of 68Ga PSMA PET/CT positivity in patients with prostate cancer
    Soydal, Cigdem
    Urun, Yuksel
    Suer, Evren
    Nak, Demet
    Ozkan, Elgin
    Kucuk, Nuriye O.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 64 (02): : 226 - 230
  • [39] Role of 68Ga-PSMA PET/CT before early salvage radiotherapy in prostate carcinoma
    Natoli, Elena
    Cavallini, Letizia
    Arcelli, Alessandra
    Mammini, Filippo
    Paolinelli, Silvia
    Galietta, Erika
    Laghi, Viola
    Buwenge, Milly
    Coco, Giorgio
    D'Alterio, Alessandra
    Morattan, Angelo
    Tamburini, Sara
    Droghetti, Matteo
    Chessa, Francesco
    Catanzaro, Calogero
    Bianchi, Lorenzo
    Schiavina, Riccardo
    Brunocilla, Eugenio
    Castellucci, Paolo
    Fanti, Stefano
    Cammelli, Silvia
    Ntreta, Maria
    Morganti, Alessio Giuseppe
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2403 - S2405
  • [40] Validation of gallium-68 PSMA-PET/CT for primary lymph node staging in prostate cancer patients
    van Kalmthout, L.
    van Melick, H.
    Lavalaye, J.
    Meijer, R.
    Kooistra, A.
    de Klerk, J.
    Braat, A.
    Kaldeway, P.
    de Keizer, B.
    Lam, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S295 - S295